Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study
- PMID: 37483327
- PMCID: PMC10357120
- DOI: 10.3233/ADR-220081
Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study
Abstract
Background: Alzheimer's disease (AD) is the most common form of dementia, accounting for 80% of all cases. Mild cognitive impairment (MCI) is a transitional state between normal aging and AD. Early detection is crucial, as irreversible brain damage occurs before symptoms manifest.
Objective: This study aimed to identify potential biomarkers for early detection of AD by analyzing urinary cytokine concentrations. We investigated 37 cytokines in AD, MCI, and cognitively normal individuals (NC), assessing their associations with AD development.
Methods: Urinary cytokine concentrations were measured in AD (n = 25), MCI (n = 25), and NC (n = 26) patients. IL6ST and MMP-2 levels were compared between AD and NC, while TNFRSF8, IL6ST, and IL-19 were assessed in AD versus MCI. Diagnostic models distinguished AD from NC, and in-silico analysis explored molecular mechanisms related to AD.
Results: Significant perturbations in IL6ST and MMP-2 concentrations were observed in AD urine compared to NC, suggesting their potential as biomarkers. TNFRSF8, IL6ST, and IL-19 differed significantly between AD and MCI, implicating them in disease progression. Diagnostic models exhibited promising performance (AUC: 0.59-0.79, sensitivity: 0.72-0.80, specificity: 0.56-0.78) in distinguishing AD from NC. In-silico analysis revealed molecular insights, including relevant non-coding RNAs, microRNAs, and transcription factors.
Conclusion: This study establishes significant associations between urinary cytokine concentrations and AD and MCI. IL6ST, MMP-2, TNFRSF8, IL6ST, and IL-19 emerge as potential biomarkers for early detection of AD. In-silico analysis enhances understanding of molecular mechanisms in AD. Further validation and exploration of these biomarkers in larger cohorts are warranted to assess their clinical utility.
Keywords: Alzheimer’s disease; biomarkers; cytokines; inflammation; mild cognitive impairment; urine.
© 2023 – The authors. Published by IOS Press.
Conflict of interest statement
The authors have no conflict of interest to report.
Figures


References
-
- (2022) 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 18, 700–789. - PubMed
-
- (2021) 2021 Alzheimer’s disease facts and figures. Alzheimers Dement 17, 327–406. - PubMed
-
- Lane CA, Hardy J, Schott JM (2018) Alzheimer’s disease. Eur J Neurol 25, 59–70. - PubMed
-
- Hu C, Yu D, Sun X, Zhang M, Wang L, Qin H (2017) The prevalence and progression of mild cognitive impairment among clinic and community populations: A systematic review and meta-analysis. Int Psychogeriatr 29, 1595–1608. - PubMed
-
- Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, Gronseth GS, Marson D, Pringsheim T, Day GS, Sager M, Stevens J, Rae-Grant A (2018) Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 126–135. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous